arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

UroGen Pharma Ltd.

URGN
$46.97 ▲ +1.34 (+2.93%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
37 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
65
Health
Good
Neutral
auto_awesome

Analytical Summary

UroGen Pharma Ltd. demonstrates solid fundamentals with strength in Return on Common Equity (%). However, watch Operating Margin (%) which shows concerning trends. Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap $2.4B
Dividend Yield
Revenue Growth 151.6%
Op. Margin -39.8%
ROIC -22.2%
FCF / Share $-0.90
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -1.61
info Valuation on last close. End-of-day price, Aug 7, 2026.

37-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$50.96M
↑ +151.6%
Net Income Profit after all expenses
$-23.57M
↑ +46.2%
Operating Margin Operating profit as % of sales
-39.8%
↑ +21.3% 2th
FCF / Share Free cash flow per share
$-0.90
↓ -1.9%
Long-Term Debt Long-term obligations
$200.00M
↑ +60.0%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
2
Returns
100
Financial Health
100
Cash Quality
68

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 12 years · 37 quarters